Pedersen, Alma B. http://orcid.org/0000-0002-3288-9401
Risbo, Nickolaj
Kafatos, George
Neasham, David
O’Kelly, James
Ehrenstein, Vera http://orcid.org/0000-0002-3415-3254
Funding for this research was provided by:
Amgen
Article History
Received: 22 July 2022
Accepted: 28 December 2022
First Online: 11 January 2023
Declarations
:
: The study was reported to the Danish Data Protection Agency through registration at Aarhus University (record number: AU-2016–051-000001, sequential number 880).
: Alma Becic Pedersen, Nikolaj Risbo, and Vera Ehrenstein do not have any conflict of interest. The Department of Clinical Epidemiology at Aarhus University Hospital is involved in studies with funding from various pharmaceutical companies as institutional research grants. One such study, specifically an ongoing regulator-mandated postauthorization safety study of denosumab among women with postmenopausal osteoporosis, funded by Amgen Inc. through institutional funding to Aarhus University, is related to and has overlapping populations with the present study. George Kafatos, David Neasham, and James O'Kelly are employees and stockholders of Amgen Ltd.